Hydroxychloroquine for COVID-19: a single center, retrospective cohort study

Introduction: The outbreak of coronavirus disease (COVID-19) in December 2019 called for a rapid solution, leading to repurposing of existing drugs. Due to its immunomodulatory effect and antiviral properties, hydroxychloroquine (HCQ) has been used in early 2020 for treatment of COVID-19 patients....

Full description

Bibliographic Details
Main Authors: Wen, Chung Ho, Yong, Wei Xin, How, Kang Nien, Khalid, Khairil Erwan, Zulkifli, Shazwani, Idris, Salmah
Format: Article
Language:English
Published: Faculty of Medicine and Health Sciences, University Putra Malaysia 2022
Online Access:http://psasir.upm.edu.my/id/eprint/101756/
http://psasir.upm.edu.my/id/eprint/101756/1/2023032211275502_MJMHS_0551.pdf
_version_ 1848863624605466624
author Wen, Chung Ho
Yong, Wei Xin
How, Kang Nien
Khalid, Khairil Erwan
Zulkifli, Shazwani
Idris, Salmah
author_facet Wen, Chung Ho
Yong, Wei Xin
How, Kang Nien
Khalid, Khairil Erwan
Zulkifli, Shazwani
Idris, Salmah
author_sort Wen, Chung Ho
building UPM Institutional Repository
collection Online Access
description Introduction: The outbreak of coronavirus disease (COVID-19) in December 2019 called for a rapid solution, leading to repurposing of existing drugs. Due to its immunomodulatory effect and antiviral properties, hydroxychloroquine (HCQ) has been used in early 2020 for treatment of COVID-19 patients. This study was conducted to evaluate the treatment outcome of HCQ monotherapy in Malaysia. Methods: A retrospective cohort study was conducted in COVID-19 ward in Hospital Kuala Lumpur (HKL), from March to April 2020. A total of 446 COVID-19 patients were recruited, only 325 patients were finally included for analysis. Statistical analysis was done using SPSS, with a significant value set at p<0.05. Results: The mean age of the patients were 38.5 ±15.5. They were majority male, (n=210, 64.6%) Malaysian (n=239, 73.5%) and Malay ethnicity (n=204, 62.8%). Ninety-one (28%) patients received HCQ monotherapy. HCQ monotherapy was associated with worse outcome (OR: 10.29, 95% CI 1.17-90.80). There was a significant difference in mean length of stay between those with and without HCQ treatment (t323=5.868, p<0.001, 95% CI, 2.56-5.31). The average length of stay for HCQ treated group was 3.84 days longer than those without treatment. 6.6% of the patient receiving HCQ monotherapy encountered adverse drug effects. Conclusion: Similar to study reported worldwide, our study demonstrated that HCQ did not improve length of stay and the outcome of COVID-19 patients.
first_indexed 2025-11-15T13:35:53Z
format Article
id upm-101756
institution Universiti Putra Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T13:35:53Z
publishDate 2022
publisher Faculty of Medicine and Health Sciences, University Putra Malaysia
recordtype eprints
repository_type Digital Repository
spelling upm-1017562024-04-30T03:54:43Z http://psasir.upm.edu.my/id/eprint/101756/ Hydroxychloroquine for COVID-19: a single center, retrospective cohort study Wen, Chung Ho Yong, Wei Xin How, Kang Nien Khalid, Khairil Erwan Zulkifli, Shazwani Idris, Salmah Introduction: The outbreak of coronavirus disease (COVID-19) in December 2019 called for a rapid solution, leading to repurposing of existing drugs. Due to its immunomodulatory effect and antiviral properties, hydroxychloroquine (HCQ) has been used in early 2020 for treatment of COVID-19 patients. This study was conducted to evaluate the treatment outcome of HCQ monotherapy in Malaysia. Methods: A retrospective cohort study was conducted in COVID-19 ward in Hospital Kuala Lumpur (HKL), from March to April 2020. A total of 446 COVID-19 patients were recruited, only 325 patients were finally included for analysis. Statistical analysis was done using SPSS, with a significant value set at p<0.05. Results: The mean age of the patients were 38.5 ±15.5. They were majority male, (n=210, 64.6%) Malaysian (n=239, 73.5%) and Malay ethnicity (n=204, 62.8%). Ninety-one (28%) patients received HCQ monotherapy. HCQ monotherapy was associated with worse outcome (OR: 10.29, 95% CI 1.17-90.80). There was a significant difference in mean length of stay between those with and without HCQ treatment (t323=5.868, p<0.001, 95% CI, 2.56-5.31). The average length of stay for HCQ treated group was 3.84 days longer than those without treatment. 6.6% of the patient receiving HCQ monotherapy encountered adverse drug effects. Conclusion: Similar to study reported worldwide, our study demonstrated that HCQ did not improve length of stay and the outcome of COVID-19 patients. Faculty of Medicine and Health Sciences, University Putra Malaysia 2022 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/101756/1/2023032211275502_MJMHS_0551.pdf Wen, Chung Ho and Yong, Wei Xin and How, Kang Nien and Khalid, Khairil Erwan and Zulkifli, Shazwani and Idris, Salmah (2022) Hydroxychloroquine for COVID-19: a single center, retrospective cohort study. Malaysian Journal of Medicine and Health Sciences, 19 (2). pp. 8-13. ISSN 1675-8544; ESSN: 2636-9346 https://medic.upm.edu.my/jurnal_kami/volume_19_2023/mjmhs_vol19_no_2_march_2023-72022 10.47836/mjmhs.19.2.3
spellingShingle Wen, Chung Ho
Yong, Wei Xin
How, Kang Nien
Khalid, Khairil Erwan
Zulkifli, Shazwani
Idris, Salmah
Hydroxychloroquine for COVID-19: a single center, retrospective cohort study
title Hydroxychloroquine for COVID-19: a single center, retrospective cohort study
title_full Hydroxychloroquine for COVID-19: a single center, retrospective cohort study
title_fullStr Hydroxychloroquine for COVID-19: a single center, retrospective cohort study
title_full_unstemmed Hydroxychloroquine for COVID-19: a single center, retrospective cohort study
title_short Hydroxychloroquine for COVID-19: a single center, retrospective cohort study
title_sort hydroxychloroquine for covid-19: a single center, retrospective cohort study
url http://psasir.upm.edu.my/id/eprint/101756/
http://psasir.upm.edu.my/id/eprint/101756/
http://psasir.upm.edu.my/id/eprint/101756/
http://psasir.upm.edu.my/id/eprint/101756/1/2023032211275502_MJMHS_0551.pdf